Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCARB1 | Q8WTV0 | 10/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.60 |
| ▸ | LYN | P07948 | 2/20 | 0.57 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | RAF1 | P04049 | 1/20 | 0.57 |
| ▸ | BRAF | P15056 | 1/20 | 0.57 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.57 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.57 |
| ▸ | AKT1 | P31749 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4418756 | 0.88 | MAPK14 (0.67) | SCARB1MAPK14LYNMAPK9ABL1 | |
| SCHEMBL1599856 | 0.85 | MAPK14 (0.58) | SCARB1MAPK14 | |
| SCHEMBL1599403 | 0.85 | MAPK14 (0.67) | SCARB1MAPK14LYNMAPK9ABL1 | |
| SCHEMBL4416952 | 0.84 | MAPK14 (0.65) | SCARB1MAPK14LYNMAPK9ABL1 | |
| SCHEMBL1599599 | 0.83 | ABL1 (0.81) | SCARB1MAPK14LYNMAPK9ABL1 | |
| SCHEMBL4413512 | 0.82 | SCARB1 (0.68) | SCARB1MAPK14LYNMAPK9ABL1 | |
| SCHEMBL4416207 | 0.82 | MAPK14 (0.63) | SCARB1MAPK14LYNMAPK9ABL1 | |
| SCHEMBL1600447 | 0.80 | MAPK14 (0.73) | SCARB1MAPK14LYNMAPK9ABL1 | |
| SCHEMBL4420018 | 0.80 | MAPK14 (0.60) | SCARB1MAPK14 | |
| SCHEMBL1600035 | 0.76 | SCARB1 (0.74) | SCARB1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7749999-B2 | Alpha-ketoamides and derivatives thereof | ITHERX PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | claimed |
| EP-1670787-A4 | CYTOKINE INHIBITORS | KEMIA INC (US) | 2009-04-22 | — | — | EP | claimed |
| EP-1670787-A2 | CYTOKINE INHIBITORS | Kemia, INC. (US) | 2006-06-21 | — | — | EP | claimed |
| US-20050107399-A1 | Cytokine inhibitors | KEMIA, INC. | 2005-05-19 | — | — | US | claimed |
| WO-2005023761-A2 | CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2005-03-17 | — | — | WO | claimed |
| US-7919617-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7897599-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | ITHERX PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-7749999-B2 | Alpha-ketoamides and derivatives thereof | ITHERX PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100093734-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093735-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| EP-1670787-A4 | CYTOKINE INHIBITORS | KEMIA INC (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-2035005-A2 | THERAPY USING CYTOKINE INHIBITORS | Kemia, INC. (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007146712-A2 | THERAPY USING CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2006091862-A2 | CYTOKINE INHIBITORS AND THEIR USE IN THERAPY | KEMIA, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-1670787-A2 | CYTOKINE INHIBITORS | Kemia, INC. (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050107399-A1 | Cytokine inhibitors | KEMIA, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005023761-A2 | CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107399-A1 | Cytokine inhibitors | TNF, IL1RN, IL1A | SCARB1 425/4885MAPK14 371/4885LYN 2904/4885 |
| US-20100093734-A1 | CYTOKINE INHIBITORS | TNF, IL1RN, IL1A | SCARB1 425/4885MAPK14 371/4885LYN 2904/4885 |
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | TNF, IL1A, IL1B | SCARB1 2585/4885MAPK14 696/4885LYN 3196/4885 |
| US-20100093735-A1 | CYTOKINE INHIBITORS | TNF, IL1RN, IL1A | SCARB1 425/4885MAPK14 371/4885LYN 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.